Alnylam appoints Nobel laureate Carolyn Bertozzi to board; Amy Schulman becomes Chair

ALNYLAM PHARMACEUTICALS, INC.

Carolyn Bertozzi, Ph.D., Nobel laureate in chemistry, elected to Board effective Jan. 5, 2023.
Bertozzi receives $55,000 annual cash retainer and option for 4,268 shares at $225.68.
Michael W. Bonney steps down as Executive Chair, continues as non-independent director.
Lead Independent Director Amy W. Schulman appointed Chair of the Board.
Board expands from 11 to 12 directors; Bertozzi to serve as Class III director until 2025 annual meeting.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Carolyn R. Bertozzi

Director

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Effective: 2023-01-05
Filed: January 6, 2023, 6:59 PM ET

Effective as of January 5, 2023, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from eleven to twelve and elected Dr. Carolyn R. Bertozzi to fill the newly created vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carolyn R. Bertozzi was elected as Director at ALNYLAM PHARMACEUTICALS, INC..

Action: elected
Role: Director

Exact text from the filing

Effective as of January 5, 2023, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from eleven to twelve and elected Dr. Carolyn R. Bertozzi to fill the newly created vacancy.

View on SEC.gov

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-003554

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.